Are we the only ones shocked by this? Despite efforts by the Obama administration to ease shortages of critical drugs, shortfalls have persisted, forcing doctors to resort to rationing…
We're still knee-deep in our follow up activities from the San Francisco conferences and receptions. Specifically, we spent the bulk of our time at the rapidly-growing Biotech Showcase…
Yesterday the Wall Street Journal summarized the current situation in antibiotic drug development and commercialization. To summarize: Big Pharma is slowly returning to antibiotic (really, antibacterial) drug discovery…
This week we're greeted with the following headlines: The FDA Approvals of 2013: A Watershed? US new drug approvals slip in 2013 vs prior year An ominous trend…
Those of us of a certain vintage will remember the days when interferon was the only option for hepatitis C patients. Then, the pegylated versions were launched and…
We've returned from another successful BIO Europe conference, this time in Vienna. We regret not having much time to walk around in Vienna. However, this did not take away…
Lacerta Bio is pleased to announce our participation in the 19th Annual BIO-Europe Conference in Vienna, Austria. As with last year's conference in Hamburg, this year's…
Ed Silverman at Pharmalot reports today that BI is closing Ben Venue once and for all: More than two years after Ben Venue Laboratories began encountering serious quality…
We recently presented a 30-minute live webinar on ways to improve your business development process. The webinar recording is available here. We also have an annotated transcript available, which you…
We've posted about the Indian pharmaceutical market before, but this report is downright shocking: U.S. inspectors visiting a factory in India owned by drugmaker Wockhardt Ltd in March…